ADCILIB 75MG

Adcilib 75 mg is a targeted therapy that contains the active ingredient palbociclib. It is classified as a member of the anticancer drug group known as cyclin-dependent kinase inhibitors. This medication is utilized for the treatment of hormone receptor-positive, human epidermal growth factor 2 negative advanced or metastatic breast cancer, which has spread to other areas of the body. Cancer is characterized by the uncontrolled and abnormal proliferation of cells. Adcilib is administered alongside certain other anticancer drugs.

Common side effects associated with the Adcilib 75 mg capsule may include nausea, vomiting, diarrhea, fatigue, hair loss, dry skin, rashes, infections, nosebleeds, reduced appetite, low blood cell counts, swelling of the lips and mouth, alterations in taste, dry eyes, blurred vision, and increased tearing. If any of these side effects are bothersome or persist, please inform your doctor.

Notify your healthcare provider if you have an allergy to Adcilib 75 mg capsule or any of its components. Prior to taking this medication, it is crucial to inform your doctor if you exhibit any signs of infection (such as fever, chills, or sore throat), liver issues, kidney problems, or intolerance to certain sugars. Seek immediate medical attention if you experience symptoms like a dry cough, chest pain, or difficulty breathing, as these may indicate lung inflammation. Ensure that you inform your physician about all medications you are taking, including supplements and herbal products, before beginning treatment with this drug. It is important to use effective birth control during treatment and for at least three weeks following the last dose. This medication is not recommended for individuals under 18 years of age.